Lenalidomide as a novel treatment of acute myeloid leukemia

Expert Opinion on Investigational Drugs

Volumn 22, Issue 3, 2013, Pages 389-397

  Chen, Yiming ^a   Borthakur, Gautam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; Chemotherapy; Cytogenetic; Lenalidomide

Indexed keywords

AZACITIDINE; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHROMOSOME 5Q; CHROMOSOME DELETION; CHROMOSOME DELETION 5; CLINICAL STUDY; CYTOGENETICS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERNATREMIA; HYPOXIA; IMMUNOMODULATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; RASH; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; THALIDOMIDE;

EID: 84873660144     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.758712     Document Type: Article

References (56)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. 2010. CA Cancer J Clin 2010;60(5):277-300
2. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29(5):487-94
3. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011;117(8):2307-18
4. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301(22):2349-61
5. Basara N, Schulze A, Wedding U, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009;23(4):635-40
6. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010;116(11):1839-48
7. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25(14):1908-15
8. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002;52(6):363-71
9. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162(14):1597-603
10. Oran B, Weisdorf DG. Survival for older patients with aml: a population based study. Haematologica 2012;97(12):1916-24
11. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107(9):3481-5
12. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the united kingdom medical research council aml11 trial. Blood 2001;98(5):1302-11
13. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and leukemia group b. N Engl J Med 1995;332(25):1671-7
14. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the eastern cooperative oncology group. Blood 2004;103(2):479-85
15. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456-65
16. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111(1):86-93
17. Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK 2(V617F) positive, del (5)(q13q33) myelodysplastic syndrome. Leukemia 2006;20(11):2063-4
18. Ford CD, Asch J, Konopa K, Petersen FB. CR with lenalidomide in del(5)(q13q33) aml relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant 2010;45(2):403-4
19. Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007;21(3):586-8
20. Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009;113(5):1002-5
21. Sugimoto Y, Sekeres MA, Makishima H, et al. Cytogenetic predictors of response to lenalidomide in myeloid malignancies without del(5q) [abstract]. Blood 2010;116(21):1637
22. Sugimoto Y, Sekeres MA, Makishima H, et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 2012;5:4
23. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10(11):775-83
24. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105(3):940-7
25. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108(1):45-51
26. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112(5):1638-45
27. Ravandi F, Cortes JE, Jones D, et al. Phase 1/2 study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28(11):1856-62
28. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase 2 study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28(4):556-61
29. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
30. Chen N, Wen L, Lau H, et al. Pharmacokinetics, metabolism and excretion of [(14)c]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 2012;69(3):789-97
31. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010;28(33):4919-25
32. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47(12):1466-75
33. Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005;23(7):625-34
34. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-6
35. Fujita J, Mestre JR, Zeldis JB, et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001;7(11):3349-55
36. Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012;26(5):893-901
37. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67(2):746-55
38. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Ak phosphorylation in vitro. Microvasc Res 2005;69(1-2):56-63
39. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140(1):36-45
40. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87(10):1166-72
41. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210-16
42. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5qsyndrome gene by RNA interference screen. Nature 2008;451(7176):335-9
43. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 2007;104(27):11406-11
44. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009;106(31):12974-9
45. Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2012; [Epub ahead of print]
46. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009;113(17):3947-52
47. Mollgard L, Saft L, Treppendahl MB, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica 2011;96(7):963-71
48. Chen Y, Kantarjian H, Estrov Z, et al. A phase 2 study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk 2012;12(5):341-4
49. Litzow MR, Othus M, Cripe LD, et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the eastern cooperative oncology group. Br J Haematol 2010;148(2):217-25
50. Giles F, Vey N, DeAngelo D, et al. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 2009;114(19):4027-33
51. Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011;117(6):1828-33
52. Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: southwest Oncology Group Study S0605. Blood 2011;118(3):523-8
53. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69(18):7347-56
54. Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006;107(8):1839-43
55. Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376(9757):2000-8
56. Ramsingh G, Westervelt P, Cashen AF, et al. A phase 1 study of concomitant high dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia 2012; Epub ahead of print